Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA
Xconomy
JUNE 21, 2019
Editing human DNA has entered the public consciousness in a big way in recent years with its increasing use in laboratories— and, in recent news that shocked the scientific community, in embryos —of tools such as CRISPR-Cas9. Locana, a gene therapy biotech in San Diego, is taking what it describes as a “parallel path” to developing therapeutics that could potentially fix diseases by changing our genetic code through altering DNA’s molecular compatriot, RNA.
Let's personalize your content